Pech M, Wieners G, Freund T, Dudeck O, Fischbach F, Ricke J, Seemann M D
Department of Radiology and Nuclear Medicine, University of Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, Germany.
Eur J Med Res. 2007 Apr 26;12(4):161-8.
PURPOSE: Evaluation of MR-guided interstitial laser thermotherapy (ILT) of colorectal liver metastases under consideration of efficacy, safety and patient survival. MATERIALS AND METHODS: Sixty-six inoperable patients with a total of 117 colorectal liver metastases were treated with MR-guided laser therapy in 96 sessions. 40.9% of patients presented metastases from rectum carcinoma, 30.3% from sigmoid carcinoma and 28.8% from colon carcinoma. Inclusion criteria were < or =5 metastases < or =5 cm in greatest diameter and no extrahepatic tumor spread. Internally water-cooled 9F power-laser-applicators were placed under CT-fluoroscopy. For MR-guided ILT, a 1064 nm Nd-YAG-lasers with a beam divider with multi applicator technique was used. The energy applied was 10 watt per centimeter diffusor length, with the diffusor length ranging from 20 to 40 mm. The mean duration of the energy application was 23 minutes (range: 15 - 37 minutes). The endpoint of the laser ablation was defined as the absence of hyperintense tumor tissue in the continuously monitored T2-w fat saturated gradient-echo sequences. Follow-up included contrast-enhanced MRI using T1- and T2-weighted spin-echo and gradient-echo sequences every three months after treatment. Survival times were calculated using the Kaplan-Meier method. RESULTS: The median follow-up was 8.7 months (mean 11.8; standard deviation 9.9; range 1 to 36). The overall median progression free survival was 6.1 months (range, 0.3 to 27+ months). Median survival was 23 months (95% CI, 17-29 months). The rate of major complications was 2.1% (n = 2) and peri-procedural mortality (30 days) was 3% (n = 2). After 3, 6, 9, and 12 months, local tumor control was 98.3%, 91.4%, 76.1%, and 69.4%, respectively. In no patient metastatic deposits along the catheter access route were found. CONCLUSIONS: In patients with colorectal liver metastases, interstitial laser thermotherapy is an effective and safe therapeutic option and therefore suitable not only in palliative situations.
目的:在考虑疗效、安全性和患者生存率的情况下,评估磁共振引导下的间质激光热疗(ILT)对结直肠癌肝转移的治疗效果。 材料与方法:66例无法手术的患者,共117处结直肠癌肝转移灶,接受了96次磁共振引导下的激光治疗。40.9%的患者转移灶来自直肠癌,30.3%来自乙状结肠癌,28.8%来自结肠癌。纳入标准为转移灶≤5个,最大直径≤5 cm,且无肝外肿瘤扩散。在CT透视引导下放置水冷式9F功率激光 applicator。对于磁共振引导下的ILT,使用了1064 nm Nd-YAG激光,配有分束器和多 applicator 技术。施加的能量为每厘米扩散器长度10瓦,扩散器长度为20至40 mm。能量施加的平均持续时间为23分钟(范围:15 - 37分钟)。激光消融的终点定义为在连续监测的T2加权脂肪饱和梯度回波序列中无高信号肿瘤组织。随访包括治疗后每三个月使用T1加权和T2加权自旋回波及梯度回波序列进行的对比增强MRI。使用Kaplan-Meier方法计算生存时间。 结果:中位随访时间为8.7个月(平均11.8个月;标准差9.9个月;范围1至36个月)。总体中位无进展生存期为6.1个月(范围,0.3至27 +个月)。中位生存期为23个月(95% CI,17 - 29个月)。主要并发症发生率为2.1%(n = 2),围手术期死亡率(30天)为3%(n = 2)。3、6、9和12个月后,局部肿瘤控制率分别为98.3%、91.4%、76.1%和69.4%。未发现沿导管进入路径有转移灶的患者。 结论:对于结直肠癌肝转移患者,间质激光热疗是一种有效且安全的治疗选择,因此不仅适用于姑息治疗情况。
J Vasc Interv Radiol. 2009-2
J Funct Biomater. 2017-6-14
Biomed Res Int. 2014
J Endocrinol Invest. 2013-1
F1000 Med Rep. 2010-12-8
Chirurg. 2010-6
J Vasc Interv Radiol. 2010-4